Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: A phase 1 trial

Authors

David S Hong, University of Texas MD Anderson Cancer Center
Brian A Van Tine, Washington University School of Medicine in St. Louis
Armin Ghobadi, Washington University School of Medicine in St. Louis
Amanda Cashen, Washington University School of Medicine in St. Louis
et al.

Journal

Nature Medicine

Publication Date

1-1-2023

Volume

29

Issue

1

First Page

104

Last Page

114

Document Type

Open Access Publication

DOI

10.1038/s41591-022-02128-z

Rights and Permissions

Hong, D.S., Van Tine, B.A., Biswas, S. et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat Med 29, 104–114 (2023). https://doi.org/10.1038/s41591-022-02128-z This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Recommended Citation

Hong, David S; Van Tine, Brian A; Ghobadi, Armin; Cashen, Amanda; and et al., "Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: A phase 1 trial." Nature Medicine. 29, 1. 104 - 114. (2023).
https://digitalcommons.wustl.edu/oa_4/1202

Additional Links

Supplemental material is available for this article at publisher site.